Related Experiment Video

Updated: Dec 15, 2025

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.6K

Association of trimethylamine N-oxide with coronary atherosclerotic burden in patients with non-ST-segment elevation

Khalid Bin Waleed1,2, Yongkang Lu1, Qiang Liu1

  • 1Department of Cardiology, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen.

Medicine
|July 8, 2020
PubMed
Abstract

Insights

Trimethylamine N-oxide (TMAO) is linked to atherosclerotic cardiovascular disease (CVD) severity in new non-ST-segment elevation myocardial infarction (NSTEMI) patients. This study explores TMAO as a potential predictor and prognostic biomarker for adverse cardiovascular events after intervention.

Area of Science:

  • Cardiovascular Medicine
  • Gut Microbiome Research
  • Biomarker Discovery

Background:

  • Trimethylamine N-oxide (TMAO), a metabolite linked to gut microbiota, is implicated in atherosclerotic cardiovascular disease (CVD) pathogenesis.
  • Previous studies have explored TMAO's association with coronary atherosclerosis in stable CAD and STEMI patients.
  • The role of TMAO in newly diagnosed non-ST-segment elevation myocardial infarction (NSTEMI) patients remains under-investigated.

Purpose of the Study:

  • To investigate the relationship between TMAO levels and the severity of coronary atherosclerosis in NSTEMI patients.
  • To evaluate TMAO as a prognostic biomarker for major adverse cardiovascular and cerebrovascular events (MACCEs) following primary percutaneous coronary intervention (pPCI).

Main Methods:

  • Prospective, single-center SZ-NSTEMI trial.
  • Coronary angiography to assess atherosclerotic severity (number of diseased arteries, SYNTAX score).
  • Isotope dilution high-performance liquid chromatography to measure pre-procedure TMAO levels.
  • Assessment of short-term (1 month) and long-term (12 months) MACCEs, including myocardial infarction, stroke, heart failure, and mortality.

Main Results:

  • This section is to be filled once the study is completed and results are available.

Conclusions:

  • The SZ-NSTEMI trial is the first cohort study to examine TMAO's association with coronary atherosclerotic burden and prognosis in NSTEMI patients.
  • Findings aim to establish TMAO as a potential predictor of atherosclerotic severity and a prognostic biomarker for adverse cardiovascular outcomes in this population.

More Related Videos

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model07:35

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Published on: December 10, 2021

2.3K
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

16.5K

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
518
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
280
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
130
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
255
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
169
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
227